Clinical and Translational Science
© American Society for Clinical Pharmacology and Therapeutics
Articles are published under the terms of the Creative Commons License as stated in the final article
Just Published Articles
- You have full text access to this OnlineOpen articleToward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
K Venkatakrishnan, C Burgess, N Gupta, A Suri, T Takubo, X Zhou, D DeMuria, M Lehnert, K Takeyama, S Singhvi and A Milton
Article first published online: 5 FEB 2016 | DOI: 10.1111/cts.12386
- You have full text access to this OnlineOpen articleABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression
CD Drenberg, S Hu, L Li, DR Buelow, SJ Orwick, AA Gibson, JD Schuetz, A Sparreboom and SD Baker
Article first published online: 4 FEB 2016 | DOI: 10.1111/cts.12366
- You have full text access to this Open Access contentSufficiency of Single-Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Cancer Patients: Lessons from the Clinical Development of Crizotinib
Paulina Selaru, Yiyun Tang, Bo Huang, Anna Polli, Keith D. Wilner, Erling Donnelly and Darrel P. Cohen
Accepted manuscript online: 3 FEB 2016 03:43AM EST | DOI: 10.1111/cts.12388
- You have full text access to this OnlineOpen articleComparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling
CH Li, RR Bies, Y Wang, MR Sharma, S Karovic, L Werk, MJ Edelman, AA Miller, EE Vokes, A Oto, MJ Ratain, LH Schwartz and ML Maitland
Article first published online: 21 JAN 2016 | DOI: 10.1111/cts.12384
- You have full text access to this OnlineOpen articleImpact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians
IS Hamadeh, MH Shahin, SM Lima, F Oliveira, L Wilson, SI Khalifa, TY Langaee, RM Cooper-DeHoff, LH Cavallari and JA Johnson
Article first published online: 19 JAN 2016 | DOI: 10.1111/cts.12385
Call for Papers
CTS welcomes submission of high-quality, scientifically sound original research papers focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of drugs. Topics of interest include:
- Precision medicine
- Translational medicine, including studies focused on Interrogation/evaluation of mechanism-of-action, human physiology, and interruption of disease pathophysiology
- Hypothesis generating non-clinical and clinical studies, including small clinical trials
- Models of human disease and their therapeutic implications
- Studies that guide Phase 2 dose selection
- Studies that identify or support biomarkers that can be used at any stage of drug development
- Studies that demonstrate effective communication between basic and clinical science
- Regulatory and public health policy implications of translational studies
- PK/PD and quantitative pharmacology as these relate to translational medicine
American Society for Clinical Pharmacology and Therapeutics
The American Society for Clinical Pharmacology and Therapeutics (ASCPT) was founded in 1900, and consists of over 2,200 professionals whose primary interest is to advance the science and practice of clinical pharmacology and translational medicine for the therapeutic benefit of patients and society. ASCPT is the largest scientific and professional organization serving the disciplines of Clinical Pharmacology and Translational Medicine. To learn more, or to apply for membership, visit: www.ascpt.org. ASCPT assumed ownership and editorial control of CTS from Wiley in early 2015. Under the new arrangements, ASCPT has selected an Editor-in-Chief and editorial team who have taken on all editorial responsibility for CTS, effective with the first 2016 issue. The editorial leadership of CTS, led by John A. Wagner, MD, PhD, as Editor-in-Chief, is comprised of a team of leading experts in the field. If you have any questions about new submissions or general inquiries about the re-launch of the journal, please contact the editorial office at email@example.com.
CTS is now fully Open Access.
The fully Open Access format of the journal, supported by an Article Processing Charge, means that all articles will be made freely available for all to read immediately upon publication. In addition, articles will publish under the Creative Commons License, enabling readers to download the article and share it with others. This platform will allow for and encourage open discourse on published works. ASCPT members receive a discounted rate on their Article Processing Charge. Click here for ASCPT membership details.
Why Submit to CTS?
CTS is the first peer-reviewed, truly interdisciplinary journal that helps bridge laboratory discovery with the diagnosis and treatment of human disease, in order to improve human health.
• Indexed in Medline and ISI
• Rigorous and rapid peer review
• Expert group of Associate Editors and Editorial Board
• Authors retain copyright and all content publishes under a Creative Commons License
• All content will be made freely available immediately upon publication, enabling the widest possible audience under the Open Access platform